In this study, we provide new insights into the prognostic value of ctDNA in resected stage III melanoma patients and emphasize the importance of serial ctDNA measurements for real-time surveillance of disease recurrence during adjuvant therapy, including BRAF/MEK targeted inhibitors. This evidence concerns the gene BRAF and melanoma.